At Cerba Research, our expert team can optimize solid tumor trials due to our extensive experience in genomics and access to a full range of sophisticated instruments and robust broad panel assays. We are also continuously verifying solid tumor international guidelines and adapting our existing panels accordingly.

Our experienced scientific team provides a flexible and responsive approach to your solid tumor trial. Note that about 50% of our oncology trials are solid tumor driven currently and may require broad panel NGS assays.

Need to assess the total number of somatic mutations? Or determine the alteration of one or multiple nucleotides of your DNA sequence? Thanks to Cerba Research and Cerba Healthcare’s experience and history in genomics, we are able to propose broad panel NGS assays. These may cover the majority of gene alterations with established, emerging, and exploratory value across lung, ovarian, breast, colon, melanoma, bladder, GIST, and rare tumors (sarcomas).

Additionally, those panels may also determine HRD score, TMB status, and MSI. Panels may detect many hallmarks of cancer such as, but not limited to:

• Single nucleotide variants (SNVs)
• Insertions-deletions (indels)
• Copy number variations (CNVs)
• Gene fusions (translocations)

Allow your scientific project a sufficient amount of time for analytical validation. If an NGS assay is already in accordance with your trial needs, the turnaround time from receipt of approved samples to result is normally 10-15 days.

With precision medicine becoming a more integral component of NSCLC treatment, molecular testing is an important step to help researchers, pathologists, and oncologists understand the genetic underpinnings of this devastating disease.

Discover how Cerba Research envisions the usage of an NGS-based broad panel assay to detect clinically relevant genetic alterations in NSCLC. Read our article on Precision medicine for NSCLC to find out more.